In the present work we showed that the combination of microRNA screening, transcriptome and proteomic profiles could identify biological differences between early and late onset ER positive BC which suggest aggressive behavior biomarkers that may represent new insights to the treatment of estrogen positive YA-BC. This evidence concerns the gene ESR1 and breast cancer.